Vaniqa is a topical skin-care product that contains eflornithine as its active component. It is marketed as a 13.9 % eflornithine cream in a tube formulation and is regulated as a prescription-only medication in Hong Kong by the Department of Health (Department of Health, Hong Kong). Vaniqa is manufactured and distributed by Galderma, a global dermatology company.
The product belongs to the Women's Health and Skin Care therapeutic area and is intended to help adult women manage unwanted facial hair growth (hirsutism). It does not remove existing hair but slows the rate at which new hair becomes visible.
Eflornithine is a reversible inhibitor of the enzyme ornithine decarboxylase (ODC). ODC is a key catalyst in the polyamine synthesis pathway, which supports the rapid cell proliferation needed for hair-follicle growth. By temporarily reducing ODC activity in the skin, eflornithine slows the conversion of hair follicles from the anagen (growth) phase to the telogen (resting) phase, resulting in a measurable reduction in the speed of facial hair emergence.
Vaniqa is approved by Hong Kong health authorities for the topical treatment of unwanted facial hair in adult women (generally aged 18 years and older). The indication specifically includes:
Vaniqa is not indicated for hair removal, scalp hair disorders, or for use on the body, limbs, or other non-facial areas.
These effects are usually transient and improve with continued use or by adjusting the amount applied.
Systemic absorption of eflornithine from the cream is negligible; therefore, clinically significant drug-drug interactions are unlikely. However:
This article provides educational information about Vaniqa and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Vaniqa is a prescription-only medication in Hong Kong. Carry the original prescription label or a doctor's note to avoid potential issues at security checkpoints. Keep the tube in its original packaging to demonstrate its legitimate medical use.
Eflornithine is a topical agent with minimal systemic absorption and is not listed as a prohibited substance by major sports or aviation regulatory bodies. However, athletes and pilots should disclose any medication use to their governing organization’s medical authority.
Vaniqa does not remove existing hair or alter its thickness. It works by slowing the emergence of new hair strands, so the visible density may appear reduced over time.
In Hong Kong, Vaniqa is supplied in a white, opaque tube with a blue cap. The label displays the brand name, concentration (13.9 % eflornithine), and the manufacturer's details (Galderma). Packaging may vary slightly in other regions but retains the same concentration and tube design.
Yes, Vaniqa can be incorporated into a routine that includes moisturizers and sunscreen. Apply Vaniqa first to clean, dry skin, allow it to absorb (approximately 5 minutes), then apply other products. If using potent actives (e.g., retinoids), monitor for increased irritation.
Once opened, Vaniqa remains stable for 12 months if kept at room temperature and the cap is tightly sealed. Always check the expiration date printed on the packaging.
The product is approved only for facial use. Applying it to the chest, abdomen, or limbs is off-label and not recommended without specific medical guidance.
Vaniqa is a prescription medication and is not covered by the public health system. Prices vary by pharmacy; generic eflornithine creams are not widely available, so the branded product may be the primary option.
Long-term studies have not shown a consistent risk of permanent skin discoloration. Mild, temporary changes in skin tone may occur if irritation is severe; discontinue use and seek medical advice if this happens.
Safety data for pregnant or lactating women are limited. Vaniqa is generally not recommended during pregnancy or while breastfeeding unless the potential benefit outweighs the uncertain risk and a clinician advises its use.
